文献速递淋巴瘤

低危HPLLs/ABC评分脾边缘区淋巴瘤患者可安全地不予治疗管理:一项西班牙前瞻性研究结果

Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study.
PubMed 文献 · Br J Haematol · 2023-06-30

这项西班牙前瞻性多中心观察性研究纳入2014至2020年诊断的181例脾边缘区淋巴瘤(SMZL)患者,分析对2014年GELTAMO SMZL指南的依从性及按HPLLs/ABC评分适应治疗策略的结局。168例可分析患者中57%遵循指南;5年总生存率77%、淋巴瘤特异性生存率93%,5年复合无事件生存率45%,A、B评分组间有显著差异(p=0.036)。数据支持HPLLs/ABC评分作为SMZL管理的实用工具,A组观察、B组利妥昔单抗为最佳治疗。

要点

  • 168例可分析患者中57%遵循2014年GELTAMO SMZL指南。
  • 5年总生存率77%,5年淋巴瘤特异性生存率93%。
  • 5年复合无事件生存率整体45%,A与B评分组间差异显著(p=0.036)。

核心结论

  • 数据支持HPLLs/ABC评分作为SMZL管理的实用工具,A组患者观察为最佳策略,B组患者利妥昔单抗为最佳治疗。

研究设计与样本

  • 西班牙前瞻性多中心观察性研究,纳入2014至2020年诊断的181例SMZL患者,168例纳入分析。
  • 评估淋巴瘤特异性生存(LSS)、复合无事件生存(CEFS)和缓解率,并分析对2014年GELTAMO SMZL指南的依从性。

主要发现

  • 168例可分析患者中57%遵循指南。
  • 利妥昔单抗联合化疗组和利妥昔单抗组的总体缓解率均高于脾切除组(p < 0.001)。
  • 5年总生存率为77%,5年LSS为93%;按所接受治疗比较5年LSS无差异(p = 0.68)。
  • 整体系列5年CEFS为45%,A与B评分组间有显著差异(p = 0.036)。
  • 诊断时或观察后接受利妥昔单抗或利妥昔单抗联合化疗的患者,其LSS和无进展生存比较无显著差异。

关键数值与推荐

  • 2014年GELTAMO SMZL指南依从率57%(168例中)。
  • 5年总生存率77%,5年LSS 93%,5年CEFS 45%。
  • A与B评分组5年CEFS差异p = 0.036。

临床怎么用

  • 作者认为HPLLs/ABC评分是SMZL管理的实用工具;作者提出A组患者观察为最佳策略,B组患者利妥昔单抗为最佳治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aims of our study were to analyse compliance with the 2014 GELTAMO SMZL Guidelines, in patients with splenic marginal zone lymphoma (SMZL), and to evaluate the outcome according to the HPLLs/ABC-adapted therapeutic strategy. Observational prospective multicenter study of 181 SMZL patients diagnosed between 2014 and 2020. Lymphoma-specific survival (LSS), composite event-free survival (CEFS) and response rates were assessed. 57% of the 168 patients included in the analysis followed the Guidelines. The overall response rate was higher in the rituximab chemotherapy and in the rituximab arms compared with the splenectomy arm (p < 0.001). The 5-year overall survival was 77% and the 5-year LSS of 93%. There were no differences in the 5-year LSS according to the treatment received (p = 0.68). The 5-year CEFS in the overall series was 45%, and there were significant differences between scores A and B (p = 0.036). There were no significant differences when comparing LSS and progression-free survival in patients treated with rituximab or rituximab chemotherapy at diagnosis or after observation. Our data support HPLLs/ABC score as a practical tool for the management of SMZL, observation as the best approach for patients in group A and rituximab as the best treatment for group B.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Muntañola A, Villalobos MT, González-Villambrosia S, et al. Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study. Br J Haematol. 2023. PMID: 37386877. doi:10.1111/bjh.18912

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。